Literature DB >> 7849321

Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes.

B A Roecklein1, B Torok-Storb.   

Abstract

A replication-defective recombinant retrovirus containing the human papilloma virus E6/E7 genes (LXSN-16 E6E7) was used to immortalize stromal cells from human marrow. The E6/E7 gene products interfere with the function of tumor-suppressor proteins p53 and Rb, respectively, thereby preventing cell cycle arrest without causing significant transformation. Twenty-seven immortalized clones designated HS-1 to HS-27 were isolated, four of which are characterized in this report. Two cell lines, HS-5 and HS-21, appear to be fibroblastoid and secrete significant levels of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage-CSF (GM-CSF), macrophage-CSF (M-CSF), Kit ligand (KL), macrophage-inhibitory protein-1 alpha, interleukin-6 (IL-6), IL-8, and IL-11. However, only HS-5 supports proliferation of hematopoietic progenitor cells when cocultured in serum-deprived media with no exogenous factors. Conditioned media (CM) from HS-5 promotes growth of myeloid colonies to significantly greater extent than a cocktail of recombinant factors containing 10 ng/mL of IL-1, IL-3, IL-6, G-CSF, GM-CSF, and KL and 3 U of erythropoietin (Epo). Two additional clones, HS-23 and HS-27, resemble "blanket" cells, with an epithelioid morphology, and are much larger, broader, and flatter when compared with HS-5 and HS-21. These lines secrete low levels of growth factors and do not support proliferation of isolated progenitor cells in cocultures. CM from HS-23 and HS-27 also fail to support growth of myeloid colonies. Both HS-23 and HS-27 express relatively high levels of VCAM-1, yet HS-27 is the only line that supports the formation of "cobblestone" areas by isolated CD34+38lo cells. We hypothesize that HS-5, HS-21, HS-23, and HS-27 represent functionally distinct components of the marrow microenvironment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7849321

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  141 in total

1.  Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical.

Authors:  Akira Sakai; Miyo Oda; Mitsuhiro Itagaki; Noriaki Yoshida; Koji Arihiro; Akiro Kimura
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

2.  Processing of CXCL12 by different osteoblast-secreted cathepsins.

Authors:  Nicole D Staudt; Andreas Maurer; Bärbel Spring; Hubert Kalbacher; Wilhelm K Aicher; Gerd Klein
Journal:  Stem Cells Dev       Date:  2012-01-04       Impact factor: 3.272

3.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Authors:  Courtney L Jones; Christy M Gearheart; Susan Fosmire; Cristina Delgado-Martin; Nikki A Evensen; Karen Bride; Angela J Waanders; Faye Pais; Jinhua Wang; Teena Bhatla; Danielle S Bitterman; Simone R de Rijk; Wallace Bourgeois; Smita Dandekar; Eugene Park; Tamara M Burleson; Pillai Pallavi Madhusoodhan; David T Teachey; Elizabeth A Raetz; Michelle L Hermiston; Markus Müschen; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Michael J Garabedian; Christopher C Porter; William L Carroll
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

4.  Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells.

Authors:  Hongjian He; Shuang Liu; Difei Wu; Bing Xu
Journal:  Angew Chem Int Ed Engl       Date:  2020-07-10       Impact factor: 15.336

5.  Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Authors:  Zachary A Hing; Rose Mantel; Kyle A Beckwith; Daphne Guinn; Erich Williams; Lisa L Smith; Katie Williams; Amy J Johnson; Amy M Lehman; John C Byrd; Jennifer A Woyach; Rosa Lapalombella
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

6.  Developing vasculature and stroma in engineered human myocardium.

Authors:  Kareen L Kreutziger; Veronica Muskheli; Pamela Johnson; Kathleen Braun; Thomas N Wight; Charles E Murry
Journal:  Tissue Eng Part A       Date:  2011-02-02       Impact factor: 3.845

7.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

8.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

9.  SLIT3-ROBO4 activation promotes vascular network formation in human engineered tissue and angiogenesis in vivo.

Authors:  Jonathan D Paul; Kareen L K Coulombe; Peter T Toth; Yanmin Zhang; Glenn Marsboom; Vytas P Bindokas; David W Smith; Charles E Murry; Jalees Rehman
Journal:  J Mol Cell Cardiol       Date:  2013-11       Impact factor: 5.000

10.  Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.

Authors:  Asish K Ghosh; Charla R Secreto; Traci R Knox; Wei Ding; Debabrata Mukhopadhyay; Neil E Kay
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.